博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300294 博雅生物

已收盘 11-22 15:00:00

{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":31.43,"timestamp":1732258989000,"preClose":32.63,"halted":0,"volume":8679953,"delay":0,"floatShares":426000000,"shares":504000000,"eps":0.3691,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.2,"latestTime":"11-22 15:00:00","open":32.67,"high":32.95,"low":31.33,"amount":278000000,"amplitude":0.0496,"askPrice":31.44,"askSize":26,"bidPrice":31.43,"bidSize":65,"shortable":0,"etf":0,"ttmEps":0.3691,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":32.63,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":35.89,"lowLimit":29.37,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"pbRate":2.17,"roa":"--","roe":"5.55%","epsLYR":0.47,"committee":0.461832,"marketValue":15849000000,"floatMarketCap":13387000000,"peRate":85.153074,"changeRate":-0.0368,"turnoverRate":0.0204,"status":1},"requestUrl":"/m/hq/s/300294/tweets","defaultTab":"tweets","newsList":[{"id":"2484165458","title":"11月20日博雅生物涨5.84%，南方医药保健灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484165458","media":"证券之星","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484165458?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:12","pubTimestamp":1732090347,"startTime":"0","endTime":"0","summary":"证券之星消息，11月20日博雅生物涨5.84%，收盘报32.28元，换手率4.02%，成交量17.13万手，成交额5.46亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共12家，其中持有数量最多的公募基金为南方医药保健灵活配置混合A。南方医药保健灵活配置混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000026786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"gpt_icon":0},{"id":"2484165466","title":"博雅生物涨5.84%，国金证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2484165466","media":"证券之星","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484165466?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:12","pubTimestamp":1732090342,"startTime":"0","endTime":"0","summary":"今日博雅生物涨5.84%，收盘报32.28元。2024年8月24日，国金证券研究员袁维发布了对博雅生物的研报《血制品实现稳定增长，静待浆源拓展落地》，该研报对博雅生物给出“买入”评级。研报中预计公司2024-2026年分别实现归母净利润5.54、6.15、6.74亿元。维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为东方财富证券的何玮。博雅生物个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000026783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"gpt_icon":0},{"id":"2484301913","title":"博雅生物(300294.SZ)：7830.86万股限售股于11月25日可上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2484301913","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484301913?lang=zh_cn&edition=full","pubTime":"2024-11-19 17:51","pubTimestamp":1732009878,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)公告，公司向特定对象华润医药控股有限公司发行的股份本次解除限售后实际可上市流通的数量为7830.86万股，占公司总股本的15.5298%。可上市流通日：2024年11月25日(星期一)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0197","BK0239","BK0046","300294"],"gpt_icon":0},{"id":"2483407846","title":"博雅生物(300294)11月8日股东户数2.64万户，较上期增加2.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483407846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483407846?lang=zh_cn&edition=full","pubTime":"2024-11-13 17:03","pubTimestamp":1731488627,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博雅生物披露，截至2024年11月8日公司股东户数为2.64万户，较10月31日增加726.0户，增幅为2.82%。在生物制品行业个股中，博雅生物股东户数低于行业平均水平，截至11月8日，生物制品行业平均股东户数为3.38万户。从股价来看，2024年10月31日至2024年11月8日，博雅生物区间涨幅为2.36%，在此期间股东户数增加726.0户，增幅为2.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300028860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"gpt_icon":0},{"id":"2481667370","title":"博雅生物最新公告：完成收购绿十字香港控股有限公司100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2481667370","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481667370?lang=zh_cn&edition=full","pubTime":"2024-11-06 18:31","pubTimestamp":1730889084,"startTime":"0","endTime":"0","summary":"博雅生物公告，公司于2024年7月17日审议通过收购绿十字香港控股有限公司100%股权的议案，使用自有资金人民币18.2亿元协议受让该股权。2024年11月6日，公司收到绿十字（香港）发来的《关于完成股东名册变更登记的函》，获悉绿十字（香港）已完成股东名册的变更登记，股权交割程序已完成。上述股东名册变更完成后，公司持有绿十字（香港）100%的股权，并开始将其纳入合并报表范围。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110600031636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"gpt_icon":0},{"id":"2481442673","title":"博雅生物：完成收购绿十字香港控股有限公司100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2481442673","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481442673?lang=zh_cn&edition=full","pubTime":"2024-11-06 18:30","pubTimestamp":1730889047,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300294","BK0239","BK0197","BK0046"],"gpt_icon":0},{"id":"2480736379","title":"博雅生物11月4日现1笔大宗交易 成交金额254.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480736379","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480736379?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:00","pubTimestamp":1730710800,"startTime":"0","endTime":"0","summary":"　　11月4日，博雅生物收涨1.55%，收盘价为31.42元，发生1笔大宗交易，合计成交量6.89万股，成交金额254.93万元。　　第1笔成交价格为37.00元，成交6.89万股，成交金额254.93万元，溢价率为17.76%，买方营业部为申万宏源证券有限公司昆明万华路证券营业部，卖方营业部为申万宏源证券有限公司昆明万华路证券营业部。　　进一步统计，近3个月内该股累计发生3笔大宗交易，合计成交金额为850.67万元。该股近5个交易日累计下跌2.90%，主力资金合计净流出3131.95万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-04/doc-incuwwwc2122400.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-04/doc-incuwwwc2122400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","300294","BK0197","BK0239"],"gpt_icon":0},{"id":"2480306072","title":"中邮证券：给予博雅生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480306072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480306072?lang=zh_cn&edition=full","pubTime":"2024-11-01 17:25","pubTimestamp":1730453128,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司蔡明子,陈成近期对博雅生物进行研究并发布了研究报告《采浆量持续稳健增长，血制品业务维持平稳发展》，本报告对博雅生物给出买入评级，当前股价为30.94元。维持推荐，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有17家机构给出评级，买入评级16家，中性评级1家；过去90天内机构目标均价为34.86。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100033978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300294"],"gpt_icon":0},{"id":"2479779765","title":"博雅生物10月31日现1笔大宗交易 成交金额305.25万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479779765","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479779765?lang=zh_cn&edition=full","pubTime":"2024-10-31 16:40","pubTimestamp":1730364000,"startTime":"0","endTime":"0","summary":"　　10月31日，博雅生物收跌0.26%，收盘价为30.97元，发生1笔大宗交易，合计成交量8.25万股，成交金额305.25万元。　　进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为595.74万元。该股近5个交易日累计下跌6.44%，主力资金合计净流出7114.73万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-10-31/doc-incumwna4037776.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-10-31/doc-incumwna4037776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0197","BK0046","300294","BK0239"],"gpt_icon":0},{"id":"2479792874","title":"万联证券：给予博雅生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479792874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479792874?lang=zh_cn&edition=full","pubTime":"2024-10-31 08:27","pubTimestamp":1730334466,"startTime":"0","endTime":"0","summary":"万联证券股份有限公司黄婧婧近期对博雅生物进行研究并发布了研究报告《点评报告：采浆量双位数同比增长，盈利水平同比提升明显》，本报告对博雅生物给出买入评级，当前股价为31.05元。　　博雅生物　　报告关键要素:　　公司2024年10月24日发布三季报。最新盈利预测明细如下：该股最近90天内共有17家机构给出评级，买入评级16家，中性评级1家；过去90天内机构目标均价为34.86。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100011900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","161027"],"gpt_icon":0},{"id":"2479214193","title":"华源证券：给予博雅生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479214193","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479214193?lang=zh_cn&edition=full","pubTime":"2024-10-30 11:57","pubTimestamp":1730260653,"startTime":"0","endTime":"0","summary":"华源证券股份有限公司刘闯,李强近期对博雅生物进行研究并发布了研究报告《采浆量稳步增长，期待华润长期赋能想象空间》，本报告对博雅生物给出买入评级，当前股价为30.86元。最新盈利预测明细如下：该股最近90天内共有16家机构给出评级，买入评级15家，中性评级1家；过去90天内机构目标均价为36.03。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000019733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300294"],"gpt_icon":0},{"id":"2479296396","title":"华鑫证券：给予博雅生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479296396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479296396?lang=zh_cn&edition=full","pubTime":"2024-10-30 08:41","pubTimestamp":1730248886,"startTime":"0","endTime":"0","summary":"华鑫证券胡博新,吴景欢近期对博雅生物进行研究并发布了研究报告《公司事件点评报告：血制品保持稳健增长，内生外延助力浆站拓展》，本报告对博雅生物给出买入评级，当前股价为31.47元。最新盈利预测明细如下：该股最近90天内共有16家机构给出评级，买入评级15家，中性评级1家；过去90天内机构目标均价为36.03。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000009729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300294"],"gpt_icon":0},{"id":"2479298227","title":"【机构调研记录】格林基金调研博雅生物、立讯精密等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2479298227","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479298227?lang=zh_cn&edition=full","pubTime":"2024-10-30 08:05","pubTimestamp":1730246745,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月29日披露的机构调研信息，格林基金近期对4家上市公司进行了调研，相关名单如下：1）博雅生物 个股亮点：参股公司罗益生物主要产品为AC流脑结合疫苗。3）恒玄科技 个股亮点：公司主营产品包括TWS耳机芯片。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000009105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HK0000320264.USD","BK0171","LU1961090484.USD","LU1997245177.USD","LU2148510915.USD","HK0000306701.USD","LU0405327494.USD","LU1997244956.HKD","LU1969619763.USD","BK0028","BK0183","LU1064131003.USD","LU0405327148.USD","LU1997245094.SGD","IE00BMPRXR70.SGD","BK0197","LU0651946864.USD","BK0214","LU1515016050.SGD","LU1051768304.USD","300294","IE00BMPRXN33.USD","IE00BPRC5H50.USD","BK0239","IE00B543WZ88.USD","BK0188","LU2495084118.USD","BK0012","BK0072","LU2476274308.USD","SGXZ49509284.SGD","LU0651947912.USD","LU2778985437.USD","BK0196","LU1051769294.HKD","IE00B5MMRT66.SGD","BK0046","LU2328871848.SGD","SGXZ81163826.USD","LU1655091616.SGD","002475","HK0000306685.HKD","LU2289578879.USD","LU2399975544.HKD","HK0000320223.HKD","LU1064130708.USD","LU1720050803.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2479847495","title":"博雅生物：10月28日召开业绩说明会，包括知名机构盈峰资本，银叶投资的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2479847495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479847495?lang=zh_cn&edition=full","pubTime":"2024-10-29 18:43","pubTimestamp":1730198604,"startTime":"0","endTime":"0","summary":"在战略扩张方面，7月公司披露收购绿十字香港控股有限公司 100%股权，为公司整合行业资源、拓展新浆站开辟新的路径，从而加速提升公司的规模与核心竞争力公司。目前，正在办理股权交割手续。这一趋势的驱动因素在于公司对于产品结构的战略调整，以及对新产品市场推广的加大投入。目前 10%静丙产品定价较高，价格约为普通静丙的两倍。采集量方面，争取同比保持有两位数以上的增速。整体而言，各类产品基本保持稳定的产品库存。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900034889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300294"],"gpt_icon":0},{"id":"2479649300","title":"国元证券：给予博雅生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479649300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479649300?lang=zh_cn&edition=full","pubTime":"2024-10-29 08:27","pubTimestamp":1730161679,"startTime":"0","endTime":"0","summary":"国元证券股份有限公司马云涛近期对博雅生物进行研究并发布了研究报告《2024三季报点评：血液品业务稳健增长，浆站拓展逐步落地》，本报告对博雅生物给出买入评级，当前股价为32.36元。最新盈利预测明细如下：该股最近90天内共有16家机构给出评级，买入评级15家，中性评级1家；过去90天内机构目标均价为36.03。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900008712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000728","300294"],"gpt_icon":0},{"id":"2478603453","title":"博雅生物(300294)10月18日股东户数2.34万户，较上期减少0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478603453","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478603453?lang=zh_cn&edition=full","pubTime":"2024-10-25 17:10","pubTimestamp":1729847450,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博雅生物披露，截至2024年10月18日公司股东户数为2.34万户，较10月10日减少223.0户，减幅为0.94%。在生物制品行业个股中，博雅生物股东户数低于行业平均水平，截至10月18日，生物制品行业平均股东户数为3.35万户。从股价来看，2024年10月10日至2024年10月18日，博雅生物区间跌幅为3.92%，在此期间股东户数减少223.0户，减幅为0.94%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500030106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300294","BK0197"],"gpt_icon":0},{"id":"2477597216","title":"华润医药(03320.HK)附属华润博雅生物首九月赚4.12亿人民币  倒退13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477597216","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477597216?lang=zh_cn&edition=full","pubTime":"2024-10-24 23:52","pubTimestamp":1729785120,"startTime":"0","endTime":"0","summary":"华润医药(03320.HK) 公布，附属华润博雅生物9月止首九个月业绩，实现营业总收入12.45亿人民币，按年下降43.2%。录得净利润4.12亿人民币，倒退13%。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-10-24 16:25。)过往派息公布日期派息事项派息内容2024/08/29中期业绩普通股息：人民币 0.083 (相当于港元 0.0908)2024/03/26末期业绩普通股息：人民币 0.154 (相当于港元 0.1697)2023/10/31第三季业绩无派息2023/08/31中期业绩无派息AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180321104350557_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180321104350557_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1390928/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03320","300294","BK0197","BK0239","BK1570","BK1191","BK0046"],"gpt_icon":0},{"id":"2477631491","title":"博雅生物(300294.SZ)发布前三季度业绩，净利润4.13亿元，同比下降11.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477631491","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477631491?lang=zh_cn&edition=full","pubTime":"2024-10-24 21:45","pubTimestamp":1729777529,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)发布2024年三季度报告，前三季度，公司实现营业收入12.45亿元，同比下降43.16%。归属于上市公司股东的净利润4.13亿元，同比下降11.07%。归属于上市公司股东的扣除非经常性损益的净利润3.36亿元，同比下降6.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294"],"gpt_icon":0},{"id":"2477183689","title":"华润医药：华润博雅生物前三季度净利润约4.12亿元，同比减少13.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477183689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477183689?lang=zh_cn&edition=full","pubTime":"2024-10-24 19:04","pubTimestamp":1729767899,"startTime":"0","endTime":"0","summary":"华润医药(03320)公布华润博雅生物2024年前9个月业绩，营业总收入约12.45亿元，同比减少43.16%;净利润约4.12亿元，同比减少13.01%。 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20241024/c662766996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["300294"],"gpt_icon":0},{"id":"2477853816","title":"华润医药(03320)：华润博雅生物前三季度净利润约4.12亿元，同比减少13.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477853816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477853816?lang=zh_cn&edition=full","pubTime":"2024-10-24 19:01","pubTimestamp":1729767714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)公布华润博雅生物2024年前9个月业绩，营业总收入约12.45亿元，同比减少43.16%;净利润约4.12亿元，同比减少13.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1199056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294","03320"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业园区惠泉路333号","stockEarnings":[{"period":"1week","weight":0.009},{"period":"1month","weight":-0.0684},{"period":"3month","weight":-0.0006},{"period":"6month","weight":-0.0316},{"period":"1year","weight":-0.0131},{"period":"ytd","weight":-0.0532}],"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","perCapita":"19073股","boardName":"医药制造业","registeredCapital":"50424万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":"　　华润博雅生物制药集团股份有限公司的主营业务以血液制品为主，集生化药、化学药、原料药为辅。公司的主要产品为血液制品业务、天安药业的糖尿病用药业务、新百药业的生化类用药业务、博雅欣和化学药业务、复大医药经销业务。公司是全国较早通过国家药品新版GMP认证的企业之一，公司生产线采用过程自动控制系统对生产过程进行控制，实现了全程CIP、SIP及关键参数的自动记录。公司严格按国家相关规定组织生产和质量控制，大大提高了产品安全性、质量可控性，产品质量指标高于国家标准。","serverTime":1732318094903,"listedPrice":25,"stockholders":"26437人(较上一季度增加2.82%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}